The stock price of Sam Chun Dang Pharm, listed on the KOSDAQ, is strong at the beginning of trading on the 5th. This surge is interpreted as a buying frenzy following the news that the Ailya biosimilar developed by Sam Chun Dang Pharm has completed its first commercial shipment.
As of 9:21 a.m. on this day, Sam Chun Dang Pharm is trading at 159,000 won, up 13,800 won (9.50%) from the previous trading day.
Sam Chun Dang Pharm announced that the first commercial product of the Ailya biosimilar has been shipped and that sales are expected to begin in July.
A company official noted, “After a long process of development, clinical trials, contracts, and obtaining permits over the past decade, exports for product sales have finally begun.” They added, “Ninety percent of the shipped products consist of prefilled syringes (PFS), which will be sold as the first Ailya biosimilar PFS not only in the respective country but also in the global market.”
He further added, “The quantity to be exported to this single country in the second half of this year is expected to exceed the annual sales volume of domestic Ailya (approximately 170,000 units), and the export volume for other regions this year has also been confirmed, with product production proceeding sequentially.”